Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Leukemia

Free Subscription 29.06.2026 2 Am J Hematol 5 Ann Hematol 1 Biochem Pharmacol 4 Blood 5 BMC Cancer 2 Bone Marrow Transplant 1 Cancer Chemother Pharmacol 1 Cancer Res 1 Cell 1 Eur J Haematol 1 J Biol Chem 1 J Clin Oncol 2 J Pediatr Hematol Oncol 4 Leuk Lymphoma 3 Leuk Res 7 Leukemia 1 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Hematol

1. BHATT VR, Wichman CS, Bouska A, Ellithi M, et al
   Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.
   Am J Hematol. 2026 Jun 26. doi: 10.1002/ajh.70428.
   PubMed         Abstract available
   
   
2. ZHANG TY, Ge AY, Hutchinson L, Higgins AW, et al
   Limited Survival Benefit and High Healthcare Utilization With AML-Directed Therapy in Older Patients With TP53-Mutated Acute Myeloid Leukemia.
   Am J Hematol. 2026 Jun 22. doi: 10.1002/ajh.70422.
   PubMed        
   
   

   
   Ann Hematol

3. MA C, Yue N, Hu W, Yang Y, et al
   Venetoclax plus Idarubicin and cytarabine as frontline induction for newly diagnosed acute myeloid leukemia in young, fit adults: a real-world study.
   Ann Hematol. 2026 Jun 19. doi: 10.1007/s00277-026-07113.
   PubMed        
   
   
4. MENG F, Al-Khafaji Z, Muzammil K, Sarbazjoda E, et al
   Biomarkers and advances in AML-MRC: from bench to bedside.
   Ann Hematol. 2026;105:127.
   PubMed         Abstract available
   
   
5. FRANSECKY L, Fiedler W, Rollig C, Sauer T, et al
   Venetoclax and Blinatumomab for adult patients with relapsed/refractory or MRD positive Ph-negative B-cell precursor ALL: phase I part of the GMALL-BLIVEN trial.
   Ann Hematol. 2026;105:109.
   PubMed         Abstract available
   
   
6. LANAMTIENG T, Mervaala-Muroke A, Toivanen L, Porkka K, et al
   Novel therapies in myeloid neoplasms show limited benefit and increased costs over 15 years of follow-up in Southern Finland.
   Ann Hematol. 2026;105:94.
   PubMed         Abstract available
   
   
7. FAN Y, Chen L, Liu S, Dang J, et al
   t(8;21)AML patients with RUNX1e6::RUNX1T19a splice variant have poor prognosis.
   Ann Hematol. 2025;104:4081-4091.
   PubMed         Abstract available
   
   

   
   Biochem Pharmacol

8. GAO J, Tian F, Tang Y, Zhu H, et al
   Dual inhibition of tubulin and DNMT by the novel letermovir derivative H62 blocks leukemia.
   Biochem Pharmacol. 2026 Jun 26:118196. doi: 10.1016/j.bcp.2026.118196.
   PubMed         Abstract available
   
   

   
   Blood

9. POLCIK L, Pethe A, Ashok D, Tissino E, et al
   CD49d governs immune synapse formation through actin rearrangements and synchronizes BCR signaling in CLL.
   Blood. 2026;147:3179-3194.
   PubMed         Abstract available
   
   
10. YANG J, Jia Y, Hu X, Zhou F, et al
    A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.
    Blood. 2026;147:3168-3178.
    PubMed         Abstract available
    
    
11. DRUCKER M, Lee D, Bowman M, Zhang X, et al
    Genotype-immunophenotype relationships in NPM1-mutated AML clonal evolution uncovered by single-cell multiomic analysis.
    Blood. 2026;147:3209-3216.
    PubMed         Abstract available
    
    
12. ZHANG W, Ye Z, Zhou X, Xiong P, et al
    FGF18 mediates fibroblast-leukemia crosstalk to promote acute myeloid leukemia progression.
    Blood. 2026 Jun 26:blood.2026033125. doi: 10.1182/blood.2026033125.
    PubMed         Abstract available
    
    

    
    BMC Cancer

13. BAKHTIYARIDOVVOMBAYGI M, Kheyrandish S, Safdari SM, Eskandrian S, et al
    A systematic review of the last two decades of NK cell-based clinical trials: state of the art of AML therapy.
    BMC Cancer. 2025;25:1461.
    PubMed         Abstract available
    
    
14. ZHAO L, Xiang X, Zhong A, Yu H, et al
    ASAH1-mediated sphingolipid metabolic reprogramming in venetoclax resistance of AML: beyond the monocytic phenotypes.
    BMC Cancer. 2025;26:36.
    PubMed         Abstract available
    
    
15. NYEKO R, Kruger M, Niyonzima N, Atwiine B, et al
    Incidence, patterns of clinical presentation, and haematological characteristics of paediatric acute myeloid leukaemia in Uganda: a retrospective analysis.
    BMC Cancer. 2026;26:244.
    PubMed         Abstract available
    
    
16. MA Y, Chang L, Wang L, Chen L, et al
    A single-center retrospective study of short-term efficacy and safety of blinatumomab in the treatment of high-risk acute lymphoblastic leukemia.
    BMC Cancer. 2026 Jun 22. doi: 10.1186/s12885-026-16389.
    PubMed         Abstract available
    
    
17. WLASIUK P, Szelest M, Paziewska M, Karczmarczyk A, et al
    Integrated analysis of IGHV rearrangements and cytogenetic abnormalities in a large chronic lymphocytic leukemia cohort (CLL-POL1).
    BMC Cancer. 2026 Jun 24. doi: 10.1186/s12885-026-16382.
    PubMed         Abstract available
    
    

    
    Bone Marrow Transplant

18. GAO WH, Wang CR, Wang LN, Wan M, et al
    Sequential CLAGE-Ven (cladribine, cytarabine, etoposide, and venetoclax) with reduced-intensity conditioning improves outcomes in patients with refractory acute myeloid leukemia: a prospective phase II study.
    Bone Marrow Transplant. 2026 Jun 25. doi: 10.1038/s41409-026-02944.
    PubMed        
    
    
19. KANELLOPOULOS A, Labopin M, Spyridonidis A, Nikolousis E, et al
    Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged >/=65: a study from the ALWP of EBMT.
    Bone Marrow Transplant. 2026 Jun 21. doi: 10.1038/s41409-026-02935.
    PubMed         Abstract available
    
    

    
    Cancer Chemother Pharmacol

20. CHENG Y, Chen J, Vigil C, Khanzadeh S, et al
    Evaluation of the pharmacokinetics of enasidenib in patients with hepatic impairment.
    Cancer Chemother Pharmacol. 2025;95:74.
    PubMed         Abstract available
    
    

    
    Cancer Res

21. FRANKHOUSER DE, Zhao D, Fu YH, Dey A, et al
    Longitudinal Single-Cell RNA-Sequencing Reveals Evolution of Micro- and Macro-states in Chronic Myeloid Leukemia.
    Cancer Res. 2026 Jun 22. doi: 10.1158/0008-5472.CAN-25-4371.
    PubMed         Abstract available
    
    

    
    Cell

22. LYU P, Agarwal G, Guo CJ, Sychla A, et al
    Genetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells.
    Cell. 2026 May 1:S0092-8674(26)00439-3. doi: 10.1016/j.cell.2026.
    PubMed         Abstract available
    
    

    
    Eur J Haematol

23. CHAOUI D, Stocker N
    Beyond Frailty Scores: Unmet Needs and Tailored Treatment Strategies in Patients With Chronic Lymphocytic Leukemia Aged >/= 80 Years.
    Eur J Haematol. 2026 Jun 22. doi: 10.1111/ejh.70248.
    PubMed         Abstract available
    
    

    
    J Biol Chem

24. ZHANG Y, Li Y, Li N, Zou C, et al
    ERK promotes miR34a/ISOC1 signaling to enhance all trans retinoic acid-induced myeloid differentiation in acute promyelocytic leukemia.
    J Biol Chem. 2026 Jun 20:113284. doi: 10.1016/j.jbc.2026.113284.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

25. FLEISCHHAUER K, Toffalori C, Cugnata F, Hofmann JA, et al
    Donor Selection and Human Leukocyte Antigen Loss Leukemia Relapse After Hematopoietic Cell Transplantation.
    J Clin Oncol. 2026 Jun 25:JCO2600113. doi: 10.1200/JCO-26-00113.
    PubMed         Abstract available
    
    

    
    J Pediatr Hematol Oncol

26. YUAN C, Wan Z, Gao J, Sun J, et al
    Diagnostic Pitfalls in Pediatric Acute Promyelocytic Leukemia: All-trans Retinoic Acid-Associated Hypercalcemia Mimicking Fungal Meningitis and the Risks of Azole Coadministration.
    J Pediatr Hematol Oncol. 2026 Jun 24. doi: 10.1097/MPH.0000000000003243.
    PubMed         Abstract available
    
    
27. EDINGTON HJ, DeGroote NP, Stevenson J, Chandrakasan S, et al
    Immunoglobulin Supplementation Practices and Effects During Pediatric B-Cell Acute Lymphoblastic Leukemia Therapy.
    J Pediatr Hematol Oncol. 2026;48:e175-e182.
    PubMed         Abstract available
    
    

    
    Leuk Lymphoma

28. HOLOPAINEN A, Lehto HR, Kuittinen T, Nuutinen M, et al
    Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.
    Leuk Lymphoma. 2026 Jun 26:1-9. doi: 10.1080/10428194.2026.2690477.
    PubMed         Abstract available
    
    
29. POMERANTZ LD, Rabe KG, Hampel PJ, Roeker LE, et al
    Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.
    Leuk Lymphoma. 2026 Jun 25:1-5. doi: 10.1080/10428194.2026.2687633.
    PubMed        
    
    
30. MOLICA S, Giannarelli D, Allsup D
    An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis.
    Leuk Lymphoma. 2026 Jun 21:1-8. doi: 10.1080/10428194.2026.2690478.
    PubMed         Abstract available
    
    
31. SETH N, Deb PQ, Tam W
    KRAS-mutated clonal hematopoiesis gives rise to lineage-divergent B-lymphoblastic leukemia/lymphoma and persistent post-therapy monocytosis.
    Leuk Lymphoma. 2026 Jun 21:1-5. doi: 10.1080/10428194.2026.2689470.
    PubMed        
    
    

    
    Leuk Res

32. KAPOOR N, Hoff FW, Jackson C, Gatell VI, et al
    Long-term remission and survival in older adults with IDH-mutated acute myeloid leukemia treated with IDH inhibitors.
    Leuk Res. 2026;167:108268.
    PubMed         Abstract available
    
    
33. ZHUANG Q, Chen C, Pan J, Zhang X, et al
    CD244 modulates bone marrow infiltrating CD8(+) T cells and serves as a prognostic and immunotherapeutic target in acute myeloid leukemia.
    Leuk Res. 2026;167:108270.
    PubMed         Abstract available
    
    
34. SAVAS EM, Bozkurt HH, Kemer NI, Yildiz S, et al
    FLAMSA versus FLAG-IDA as salvage therapy in adults with relapsed/refractory acute myeloid leukemia and acute lymphoblastic leukemia: A single-center real-world retrospective study.
    Leuk Res. 2026;167:108271.
    PubMed         Abstract available
    
    

    
    Leukemia

35. MAZZERA L, Abeltino M, Lombardi G, Cantoni AM, et al
    Retraction Note: MEK1/2 regulate normal BCR and ABL1 tumor-suppressor functions to dictate ATO response in TKI-resistant Ph+ leukemia.
    Leukemia. 2026 Jun 24. doi: 10.1038/s41375-026-03026.
    PubMed        
    
    
36. YBARRA TK, Sathianathen RS, Hamidi R, Hijiya N, et al
    Immunological mechanisms and therapeutic advances in chronic myeloid leukemia.
    Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03006.
    PubMed         Abstract available
    
    
37. VASSEUR L, Duployez N, Lambert J, Lapillonne H, et al
    Genomic landscape of acute myeloid leukemia in adolescents and young adults.
    Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03010.
    PubMed        
    
    
38. MANSOUR AG, Huang Y, Pemberton JP, Alsouqi A, et al
    Outcomes of patients with chronic lymphocytic leukemia discontinuing covalent Bruton tyrosine kinase inhibitors due to adverse events.
    Leukemia. 2026 Jun 25. doi: 10.1038/s41375-026-03005.
    PubMed        
    
    
39. HOU Y, Xing Y, Chen C, Su D, et al
    Small interfering RNA-mediated silencing of mutant NPM1 suppresses acute myeloid leukemia via reversing KAT7 and p300-mediated histone acetylation.
    Leukemia. 2026 Jun 26. doi: 10.1038/s41375-026-03014.
    PubMed         Abstract available
    
    
40. YAN Y, Zhou Y, Chen W, Wang J, et al
    MYD88 variants in chronic lymphocytic leukemia exhibit distinct biological behaviors and prognostic implications.
    Leukemia. 2026 Jun 26. doi: 10.1038/s41375-026-03019.
    PubMed        
    
    
41. KOVACH AE, Ding YY, Lamble AJ, Bernt K, et al
    Plasticity under pressure: biology and detection of lineage switch in acute leukemia.
    Leukemia. 2026 Jun 26. doi: 10.1038/s41375-026-03020.
    PubMed         Abstract available
    
    

    
    PLoS One

42. GIM JA, Kwak K, Park Y, Kim BS, et al
    Potential of extracellular vesicle-derived microRNAs as a platform for biomarker discovery in acute lymphoblastic leukemia.
    PLoS One. 2026;21:e0352501.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum